Hodgkin Lymphoma | sciencenewsnet.in

Building an International Consortium to Enhance Decision Making in Hodgkin Lymphoma

Findings and the development of a new international consortium known as HoLISTIC are being shared as part of a poster presentation at the virtual 2020 American Society for Clinical Oncology Annual Meeting taking place this week.

Announcement

CAR-T immunotherapy for lymphoma studied at UNC Lineberger receives fast-track designation from FDA

March 9, 2020 sarah Jonas CAR-T, CAR-T cell therapy, Hodgkin Lymphoma, Lymphoma

Based on proof-of-concept results from clinical trials at University of North Carolina Lineberger Comprehensive Cancer Center and Baylor College of Medicine, an investigational cellular immunotherapy for Hodgkin lymphoma has received a Regenerative Medicine Advanced Therapy designation from the U.S. Food and Drug Administration.

Research Results

Treatment with PD-1 inhibitor prior to stem cell transplant is safe, effective for patients with classic Hodgkin lymphoma, study finds

December 9, 2019 sarah Jonas 0 Comments American Society Of Hematology, American Society of Hematology Annual Meeting, Dana Farber Cancer Institute, Graft Versus Host Disease, Hodgkin Lymphoma, Lymphoma, stem cell tranplantation, Stem Cell Transplant

A new analysis shows that a donor stem cell transplant following treatment with an immune checkpoint inhibitor is generally safe and produces good outcomes for patients with Hodgkin lymphoma.

Research Results

Racial Disparities in Survival Outcomes Shown in Pediatric Hodgkin Lymphoma Patients

September 17, 2019 sarah Jonas 0 Comments ASTRO 2019, Hodgkin Lymphoma, New Jersey, pediatric Hodgkin lymphoma, Racial Disparities, Rutgers University

In what is believed to be the largest dataset study to date examining the role of race on survival outcome for pediatric patients with Hodgkin lymphoma, investigators at Rutgers Cancer Institute of New Jersey have found that black patients have significantly worse overall survival at five years than white patients when accounting for all available clinical variables.